Frederiksberg, Denmark

Vibeke Miller Breinholt

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Vibeke Miller Breinholt: Innovator in Growth Disorders Treatment

Introduction

Vibeke Miller Breinholt is a notable inventor based in Frederiksberg, Denmark. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of growth disorders. Her innovative work has led to the development of a unique combination therapy that utilizes controlled-release CNP agonists.

Latest Patents

Vibeke holds 1 patent for her invention titled "Combination therapy with controlled-release CNP agonists." This patent describes a combination of a CNP agonist and at least one further biologically active moiety or drug. The invention aims to treat or prevent disorders that benefit from stimulating growth. The pharmaceutical compositions she developed comprise at least one CNP agonist, preferably in a controlled-release form, and are intended for use as a medicament in treating such disorders.

Career Highlights

Vibeke Miller Breinholt is associated with Ascendis Pharma Growth Disorders A/S, where she continues to advance her research and development efforts. Her work is pivotal in creating effective treatments for patients suffering from growth-related disorders.

Collaborations

Throughout her career, Vibeke has collaborated with esteemed colleagues, including Lars Holten-Andersen and Kennett Sprogøe. These partnerships have enhanced her research and contributed to the success of her innovative projects.

Conclusion

Vibeke Miller Breinholt is a pioneering inventor whose work in combination therapies for growth disorders showcases her commitment to improving patient outcomes. Her contributions to the field are invaluable and continue to inspire future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…